Drugs / Y-90-DOTATOC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05568017 | Sep 2020 → Sep 2022 | pancreatic neuroendocrine tumor | European Institute of Oncology | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y-90-DOTATOC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05568017 ↗ |
| Known as | 90Y-DOTATOC | “Patients with unresectable or borderline resectable pNETs will recive PRRT with 90Y-DOTATOC” NCT05568017 ↗ |
| Modality | Peptide | “The two most commonly used radiopeptides, 90Y-DOTATOC and 177Lu-DOTATATE, produce overall objective response rates of 15-35%.” NCT05568017 ↗ |